[The future of antifungal agents. Non azole antifungal agents]

Nihon Ishinkin Gakkai Zasshi. 1999;40(3):157-61. doi: 10.3314/jjmm.40.157.
[Article in Japanese]

Abstract

We investigated the efficacy of non-azole antifungal agents. Long circulating immunoliposomal amphotericin B was potent in murine invasive pulmonary aspergillosis. The concentration of AMPH-B was still high in the lung after 6 hours of 34A-PEG-liposomal AMPH-B. Lipid nanosphere amphotericin B (NS-718) showed efficacy against pulmonary aspergillosis in rats and pulmonary cryptococcosis in mice. The renal toxicity of NS-718 was estimated to be lower than that of AMPH-B from the results of the toxicity study in the rat infusion model. FK 463, a novel (1,3)-beta-D-glucan synthase inhibitor, showed efficacy against azole-resistant Candida albicans in murine experimental disseminated candidiasis. FK463 could be a promising drug and the therapy of choice for azole resistant C. albicans infection.

Publication types

  • Review

MeSH terms

  • Amphotericin B* / administration & dosage
  • Amphotericin B* / pharmacology
  • Animals
  • Antifungal Agents* / administration & dosage
  • Antifungal Agents* / pharmacology
  • Drug Carriers
  • Echinocandins
  • Flucytosine
  • Fungi / enzymology
  • Glucosyltransferases / antagonists & inhibitors
  • Lipopeptides
  • Lipoproteins / pharmacology
  • Liposomes
  • Membrane Proteins*
  • Micafungin
  • Mice
  • Mycoses / drug therapy
  • Peptides, Cyclic / pharmacology
  • Rats
  • Schizosaccharomyces pombe Proteins*

Substances

  • Antifungal Agents
  • Drug Carriers
  • Echinocandins
  • Lipopeptides
  • Lipoproteins
  • Liposomes
  • Membrane Proteins
  • Peptides, Cyclic
  • Schizosaccharomyces pombe Proteins
  • Amphotericin B
  • Flucytosine
  • Glucosyltransferases
  • 1,3-beta-glucan synthase
  • Micafungin